ACA
NKTR icon

Atlas Capital Advisors’s Nektar Therapeutics NKTR Stock Holding History

Atlas Capital Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.79K Hold
40
– – ﹤0.01% 954
2026
Q1 		$2.88K Hold
40
– – ﹤0.01% 869
2025
Q4 		$1.69K Buy
+40
New +$2.24K ﹤0.01% 856
2025
Q2 		$1.03K Hold
40
– – ﹤0.01% 881
2025
Q1 		$408 Hold
40
– – ﹤0.01% 950
2024
Q4 		$558 Buy
+40
New +$705 ﹤0.01% 900
2024
Q3 		– Sell
-40
Closed -$744 – 942
2024
Q2 		$744 Buy
+40
New +$843 ﹤0.01% 860
2024
Q1 		– Sell
-40
Closed -$339 – 942
2023
Q4 		$339 Hold
40
– – ﹤0.01% 873
2023
Q3 		$357 Hold
40
– – ﹤0.01% 850
2023
Q2 		$345 Hold
40
– – ﹤0.01% 870
2023
Q1 		$421 Hold
40
– – ﹤0.01% 881
2022
Q4 		$1.36K Hold
40
– – ﹤0.01% 846
2022
Q3 		$1.92K Hold
40
– – ﹤0.01% 836
2022
Q2 		$2.28K Hold
40
– – ﹤0.01% 902
2022
Q1 		$3.23K Hold
40
– – ﹤0.01% 824
2021
Q4 		$8.11K Hold
40
– – ﹤0.01% 745
2021
Q3 		$10.8K Hold
40
– – ﹤0.01% 716
2021
Q2 		$10.3K Hold
40
– – ﹤0.01% 738
2021
Q1 		$12K Hold
40
– – ﹤0.01% 654
2020
Q4 		$10.2K Buy
+40
New +$10.3K ﹤0.01% 589
2020
Q3 		– Sell
-40
Closed -$13.9K – 488
2020
Q2 		$13.9K Hold
40
– – ﹤0.01% 583
2020
Q1 		$10.7K Hold
40
– – ﹤0.01% 580
2019
Q4 		$13K Hold
40
– – ﹤0.01% 572
2019
Q3 		$10.9K Hold
40
– – ﹤0.01% 570
2019
Q2 		$21.3K Sell
40
-46
-53% -$23.1K 0.01% 552
2019
Q1 		$43.1K Hold
86
– – 0.02% 432
2018
Q4 		$42.2K Sell
86
-360
-81% -$217K 0.02% 424
2018
Q3 		$360K Buy
446
+406
+1,015% +$347K 0.12% 215
2018
Q2 		$29K Hold
40
– – 0.01% 424
2018
Q1 		$63.8K Buy
+40
New +$51.5K 0.02% 401

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Atlas Capital Advisors's NKTR Position: Q2 2026 in Review

Atlas Capital Advisors held its Nektar Therapeutics (NKTR) position steady in Q2 2026 at 40 shares worth $2.79K. The position accounts for ﹤0.01% of the portfolio, ranked #954.

Atlas Capital Advisors first reported a position in NKTR in Q1 2018 and has held it in 30 quarters since. The position peaked at $360K in Q3 2018. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Atlas Capital Advisors held 40 shares of Nektar Therapeutics worth $2.79K as of Q2 2026.
  • Atlas Capital Advisors left its Nektar Therapeutics share count unchanged in Q2 2026.
  • Nektar Therapeutics made up ﹤0.01% of Atlas Capital Advisors's portfolio in Q2 2026, its #954 holding.
  • Atlas Capital Advisors first reported a position in Nektar Therapeutics in Q1 2018 and has held it in 30 quarters since.
  • Atlas Capital Advisors's Nektar Therapeutics position peaked at $360K in Q3 2018.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Atlas Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.